Bofanglutide
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 420
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| GZR18 Dose Level 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| GZR18 Dose Level 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Semaglutide(Wegovy® )2.4 mg | Obesity or overweight | 2.4 mg | n/r | n/r | n/r |